|
Dr Michael Gillam
CEO HealthLabs, Health Data Innovations Scholar,
MedStar Institutes for Innovation, Singularity University, Healthcare Faculty,
San Francisco, USA
|
Michael Gillam is CEO of
HealthLabs, a discovery automation company for Big Data. He is also the chief
clinical judge for the Qualcomm Tricorder XPrize and served as a judge on the
Nokia Sensing XPrize. Dr Gillam helped
build and sell companies to WebMD and Microsoft and is a former founding
director of the Microsoft Healthcare Innovation Lab where he also served as a
partner level executive in Microsoft. He has advised health ministries, Fortune
500 companies, and NGOs regarding their healthcare data strategies nationally
and internationally particularly in China and the Middle East.
Dr Gillam was research director for the data aggregation solution,
Azyxxi, which was acquired by Microsoft in 2006 to become one of their flagship
products for healthcare, renamed Amalga™.
He is a physician dual-board certified in emergency medicine and medical
informatics who trained, practiced, and taught at Northwestern University in
Chicago. He’s written over fifty papers
and abstracts and has eleven patents in healthcare technology. He has served as
Chair of Informatics for both the Society for Academic Emergency Medicine and
the American College of Emergency Physicians.
He founded and ran healthcare innovation labs in Microsoft and in
Washington D.C. He has led projects spanning: advanced data visualization;
electronic medical records technology; anomalous event detection; natural
language processing (NLP); gesture based interfaces; de-identification;
personal health records (PHRs); augmented reality; and medical robotics.
Exponential Healthcare
The future of healthcare is being reshaped by exponentially advancing trends in genomics,
information science, artificial intelligence, and automation which is creating
breakthroughs in care and the way we deliver it. From 3D printing to consumer
health wearables, point of care decision support to “big data” discovery,
synthetic biology to new gene-based therapies - anticipating and leveraging
these exponential trends can be key to
thriving and making a difference in this new emerging world of health.
|
|